Tag Archives: non-hodgkin’s lymphoma

November, 2018

August, 2018

September, 2017

August, 2017

July, 2017

March, 2017

  • 30 March

    Genmab Discontinues Mid-Stage Non-Hodgkin’s Lymphoma Study

    Copenhagen, Denmark; March 30, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its collaboration partner for daratumumab, Janssen Biotech, Inc., has decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL).  The study …

November, 2015

  • 25 November

    Genmab Halts Late-Stage Lymphoma Trial

    Copenhagen, Denmark; November 23, 2015 – Genmab A/S (OMX: GEN) announced today that the Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin’s lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen will be stopped …